International prognostic scoring system for Waldenstrom macroglobulinemia. - Wikidata - wikimedia - TriplyDB

International prognostic scoring system for Waldenstrom macroglobulinemia.

International prognostic scoring system for Waldenstrom macroglobulinemia.

http://www.wikidata.org/entity/Q46131613

about

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia Waldenstrom's macroglobulinemia: Recent advances in biology and therapy Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: my way.Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia.Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea.Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcome Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.Diagnosis and management of neuropathies associated with plasma cell dyscrasias.Waldenstrom macroglobulinemia with CD5+ expression presented as cryoglobulinemic glomerulonephropathy: a case report New Therapeutic Approaches for Waldenstrom Macroglobulinemia Waldenstrom macroglobulinemia: prognosis and management.Novel agents in Waldenström macroglobulinemia.Novel agents in Waldenstrom Macroglobulinemia.Splenic re-irradiation for waldenstrőm's macroglobulinemia.How to manage Waldenstrom's macroglobulinemia.Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.Candidate genes of Waldenström's macroglobulinemia: current evidence and research.Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.Emerging drugs for Waldenström's macroglobulinemia.Hematopoietic cell transplantation for Waldenström macroglobulinemia.Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation.Risk stratification in Waldenström macroglobulinemia.

P2860

Q24634360-6EFB6995-BF53-4F7E-904E-D71C44AE286C Q28237372-7EED33EE-BBEA-4D8D-B4CE-D5E2955F6358 Q28269017-404F9602-AAA2-428D-9412-16F0188F554B Q28290236-8D555E37-E864-43B0-B988-2AD91B4FC8E1 Q28291793-BF039EBA-F8DC-40A8-8AB5-A4CC4B2F6B4B Q28307039-3FABAD47-A7E6-4945-800C-090B1D6CBCB1 Q30275582-7C3848E7-1B76-4610-8AE8-6577A7D64A28 Q33388196-B9F8EFDB-9EC2-4C09-A524-DFCE479AE081 Q33395066-71DBDA35-0977-45E2-BAD1-B06C8C68BEF3 Q33400780-FF145277-7A9B-4A38-8C87-E4FC5494560C Q33402669-4C0EA971-EEF2-447A-AFF5-2A2765EA5645 Q33405096-81C83BDE-66A0-4CA8-88A7-E89CCC831638 Q33408517-D8B3D91F-6D95-4F16-A45A-CDE385B7C30C Q33414529-AEF816CC-BDF9-4723-B329-B61B6EAEB910 Q33421444-9952FAD7-9715-4EEC-B5A3-45CA1A8B3583 Q33434251-13A04B69-C298-4C4E-9A02-93DFA56B6BBB Q33436642-3E0D571F-2A18-4BDE-82A3-09ADAF186DE9 Q33438490-33029DBF-7230-499D-8D51-B3FDBF051B4E Q33707455-2B1367B0-76D3-460F-92B8-A33F38CF7048 Q33711127-C0E788A9-AA59-4A7D-986A-03C5A3F6D8A8 Q33786873-BBDB2A74-D589-495B-9745-7124A1B40CFE Q33824350-E16F62D2-B110-4827-BBBB-2B2AC12B3484 Q34101118-E9898427-DB6D-48B9-A087-770CB6BF9BCE Q34106817-01B674B3-3ACF-4CF5-8C25-8E803C3C3B90 Q34542980-C64B9F41-5495-4929-A4F0-5BDDC7E8E8DB Q34555067-F18A56D2-749B-4D8B-8D0E-047DEEAF36A2 Q35009892-D0E02966-F48A-439A-8BA2-F1C3B997D2EB Q35176177-0EF3AE70-8270-4C46-BEE6-2F818F12840B Q35244911-E3519B5C-9F62-4ABC-BD60-D7C05F247F12 Q35429544-6CC1326C-2036-4EE6-9DD1-F8654AB3B633 Q36117791-96FEBAE6-9490-442F-B4D0-A8125E517427 Q36192577-43100E7B-8558-4B96-9FD9-0A11A7453963 Q36764811-82DE32E3-13BD-4FE8-BC33-E47202C4B80E Q36862542-FE0057D6-578C-41A5-B362-61DD1683C8C0 Q37074275-A803AC80-773C-4342-8F48-6AC40A757070 Q37499211-330C936B-5950-443B-BD75-9479F7CD9F01 Q37847176-379B9488-E25B-49D6-AE12-E8E731D2FCD2 Q37875673-59260341-7208-4A49-BFAF-B4E9029DC02A Q37901235-D9B73728-407B-42D6-9442-E85376247CC3 Q37999886-72DF9027-072F-46CF-A27A-80E824CD6C22

P2860

International prognostic scoring system for Waldenstrom macroglobulinemia.

http://www.wikidata.org/entity/Q46131613

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

International prognostic scoring system for Waldenstrom macroglobulinemia.

@en

International prognostic scoring system for Waldenstrom macroglobulinemia.

@nl

type

label

International prognostic scoring system for Waldenstrom macroglobulinemia.

@en

International prognostic scoring system for Waldenstrom macroglobulinemia.

@nl

prefLabel

International prognostic scoring system for Waldenstrom macroglobulinemia.

@en

International prognostic scoring system for Waldenstrom macroglobulinemia.

@nl

P1433

Q46131613-A10F3573-3594-4E3D-82A2-5D96B6C574E0

P1476

Q46131613-A3D68A5F-C581-4B4A-AE8C-30251B20D7CF

P2093

Q46131613-16AD0365-0564-4B6A-9508-E2B22A42F2DF

Q46131613-2B6396FC-CBC4-44CF-8A1C-A9B42FFE4113

Q46131613-3917449C-C250-4C04-8C25-91F638F22C7B

Q46131613-545247B6-D2B7-4E10-B773-D20C9BFC0044

Q46131613-6BC395CC-63ED-4C48-BE6A-384225E9BBB2

Q46131613-81C7B751-E65D-493B-B46E-CB2AAEC695FA

Q46131613-9550A17D-3BF1-4647-AC96-D44FEACBA0A9

Q46131613-B3E272A0-18E2-4567-A7A9-B740ED0C6F03

P304

Q46131613-3519786A-AF8B-41B2-A1FB-51594938DE03

P31

Q46131613-011F0093-C981-4905-B07B-72D6BA0E88C5

P356

Q46131613-CA399937-B19A-4CD2-A16E-089732F2F2C1

P407

Q46131613-EEA0A26C-5D12-4483-A902-C805B60834DC

P433

Q46131613-CAC459A0-86D9-474A-9D0C-EE74589D507C

P478

Q46131613-1C67D694-DCA1-48F1-9408-199438887949

P50

Q46131613-1139ABC9-E1EF-423A-9F50-41E8A6FD8EF9

Q46131613-3E5E27A9-6C4A-4363-B2E7-3702BA7267C3

Q46131613-5FEA195E-28C5-462A-82B6-0BA97025F3CB

Q46131613-7814AFD8-C115-47B6-BDAC-C7484CA66066

Q46131613-7E943CCA-79AB-4A21-8C49-644FCC50294B

Q46131613-D658FB9E-70CB-430A-BEC1-32284CA63946

P577

Q46131613-9280E4A8-E979-4710-A757-82BF8F4B7AB5

P5875

Q46131613-A04465D7-7D84-448C-B207-85DEF57C276A

P698

Q46131613-39DBD660-536D-4BB3-890E-5A9C845C968F

P356

BLOOD-2008-08-174961

P1433

P1476

International prognostic scoring system for Waldenstrom macroglobulinemia.

@en

P2093

Alain Duhamel

http://www.w3.org/2001/XMLSchema#string

Jason McCoy

http://www.w3.org/2001/XMLSchema#string

John Crowley

http://www.w3.org/2001/XMLSchema#string

Madhav V Dhodapkar

http://www.w3.org/2001/XMLSchema#string

Paolo Gobbi

http://www.w3.org/2001/XMLSchema#string

Pierre Morel

http://www.w3.org/2001/XMLSchema#string

Steven P Treon

http://www.w3.org/2001/XMLSchema#string

Veronique Leblond

http://www.w3.org/2001/XMLSchema#string

P304

4163-4170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-08-174961

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Ramón García-Sanz

Giampaolo Merlini

Meletios A. Dimopoulos

P577

2009-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23983229

http://www.w3.org/2001/XMLSchema#string

P698

19196866

http://www.w3.org/2001/XMLSchema#string